Oroxindin inhibits macrophage NLRP3 inflammasome activation in DSS-induced ulcerative colitis in mice via suppressing TXNIP-dependent NF- κB pathway.

In conclusion, these results demonstrate that oroxindin could be absorbed by the colon and attenuate inflammatory responses via inhibiting NLRP3 inflammasome formation and activation, which is related to the inhibitory effect on TXNIP-dependent NF-κB-signaling pathway. Hence, oroxindin has the potential of becoming an effective drug for treating UC.
PMID: 31937929 [PubMed - as supplied by publisher]

Source: Acta Pharmacologica Sinica - January 13, 2020 Category: Drugs & Pharmacology Authors: Liu Q, Zuo R, Wang K, Nong FF, Fu YJ, Huang SW, Pan ZF, Zhang Y, Luo X, Deng XL, Zhang XX, Zhou L, Chen Y Tags: Acta Pharmacol Sin Source Type: research